TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT05753930: A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converte

Sponsor: Hansa Biopharma AB · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$398,400

Rescue Site Savings

+$265,600

Unlock Full NCT05753930 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT05753930 Rescue Dossier →